Business Standard

Monday, December 23, 2024 | 06:00 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Bharat Biotech's Covaxin shows 77.8% efficacy in phase 3 trial data: Report

Covaxin has shown the efficacy from the trial conducted on 25,800 subjects, according to a news report

Covaxin
Premium

BS Web TeamANI
Bharat Biotech's Covaxin is said to have shown 77.8 % efficacy in phase 3 trial data in review by Subject Expert Committee under the drug regulator, sources told ANI on Tuesday.

According to the data submitted, Covaxin has shown efficacy of 77.8% from the trial conducted on 25,800 subjects, according to a news report

The meeting took place before Bharat Biotech's 'pre-submission' meeting on Wednesday with the World Health Organization (WHO), for the approval for their Covid vaccine.

The Hyderabad-based Covid vaccine manufacturing company submitted data from the phase 3 clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in